patent.fyi
Applications  /  US 2026/0355113
United States Patent Application Publication

US 2026/0355113 A1

Published
Nov 12, 2026
Filed
Jun 22, 2026
Earliest date on the face
Dec 22, 2023
Classification
A61K 9/1271
First published here
Nov 19, 2026

Generated automatically. Not reviewed by a person. Not legal advice or an opinion.

Section 1 · machine-generated

What if?

Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.

1.1Steric stabilization near zero

What ifWhat if the liposome had a zeta potential near 0 mV and a hydrated polymer layer kept the vesicles dispersed?
Claim language“a zeta potential of 2 to 25 mV”

Polyethylene glycol chains extend into water from lipid anchors in the outer leaflet. Overlap of the hydrated chains creates steric repulsion when vesicles approach, limiting aggregation even at a zeta potential near 0 mV.

1.1Higher positive zeta potential

What ifWhat if the liposome had a zeta potential of +35 mV in the ligand-coupling medium?
Claim language“a zeta potential of 2 to 25 mV”

A quaternary ammonium lipid fraction is adjusted until electrophoretic light scattering gives +35 mV in the low-ionic-strength coupling medium before ligand addition. Negatively charged ligands adsorb to the exposed ammonium headgroups through electrostatic attraction.

Section 2 · machine-generated

Variations

Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.

Other field of use

Fluorescent tracer for water filtration

A benchtop water filtration rig uses positively charged liposomes containing encapsulated fluorescein as particle tracers. A size exclusion column removes free dye before the liposome suspension enters the membrane feed line. Feed and permeate samples are treated with detergent to release the encapsulated dye, and a fluorometer measures the fraction of the tracer that passes through the membrane.

Component substitution

Liposomes with a protonatable surface lipid

A bilayer of phosphatidylcholine and cholesterol incorporates 1,2-dioleoyl-3-dimethylammonium-propane as the surface charge component in place of distearoylethyl dimonium chloride. An acidic aqueous buffer protonates the tertiary amine on the lipid. The fraction of the protonatable lipid and the buffer pH are adjusted to give a zeta potential of 10 to 15 mV in the final dispersion.

Parameter or scale variation

Liposomes below one hundred nanometers

A hydrated lipid dispersion containing encapsulated riboflavin passes through a 100 nm membrane followed by a 50 nm membrane. Dynamic light scattering measures the hydrodynamic diameter, with a target average of 60 to 90 nm. Electrophoretic light scattering measures a target zeta potential of 10 to 15 mV at 25 °C in the final dispersion medium.

Combination with existing systems

Liposome application in a skin diffusion cell

A vertical diffusion cell holds excised skin between an upper donor chamber and a lower receptor chamber, with the outer skin surface facing the donor. The donor chamber receives a measured volume of positively charged liposomes carrying fluorescein. Samples from the stirred receptor chamber are collected at fixed intervals, and fluorescence measurements track the amount of tracer that crosses the skin.

Separate storage in a dual chamber dispenser

A dual chamber dispenser holds positively charged liposomes in one reservoir and a dilute sodium hyaluronate solution in the other. Linked pistons meter both liquids into a static mixing nozzle, where the anionic polymer adsorbs onto the liposome surfaces. The polymer concentration sets the amount delivered per stroke and is adjusted so the mixed dispersion retains a positive zeta potential.

Automated or data-driven variant

Automated lipid blending with charge feedback

Two metering pumps feed separate solutions of the neutral bilayer lipid and the cationic lipid into a mixer supplied with a constant aqueous flow. An automated sampler removes solvent from an aliquot, exchanges it into a fixed measurement buffer, and sends it to an electrophoretic light scattering instrument. Software adjusts the ratio of the lipid streams at constant total lipid input until two successive samples measure between 10 and 15 mV.

Specific version of a part

Twelve millivolt release target

A cationic lipid is blended with phosphatidylcholine, and the blend ratio is adjusted to target a zeta potential of +12 mV. Electrophoretic light scattering verifies the target in 1 mM potassium chloride at pH 7.0 and 25 °C.

Eighteen millivolt ligand coating

An anionic polysaccharide is added incrementally to liposomes containing a quaternary ammonium lipid. Adsorption shifts the zeta potential toward zero, and the addition stops at +18 mV as measured in the coating buffer at 25 °C.

Section 3 · quoted from USPTO records

Other work

Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.

Document AUS 9,233,094 B2
Published
Jan 12, 2016
Filed
May 4, 2006
Class
A61K 31/337
Document BUS 9,827,196 B2
Published
Nov 28, 2017
Filed
Dec 4, 2015
Class
A61K 9/1272
Claim 1
Document A
Document B
1.1the liposome has a zeta potential of 2 to 25 mV, preferably 5 to 20 mV, more preferably 10 to 15 mV.
The liposomal preparation is characterized by having a positive zeta potential in about 0.05 M KCl solution at about pH 7.5 at room temperature.
A · US 9,233,094 B2 · ¶ 64
The liposomal preparation is characterized by having a positive zeta potential in about 0.05 M KCI solution at about pH 7.5 at room temperature.
B · US 9,827,196 B2 · ¶ 64

An empty cell means only that no passage was reproduced there.

Statements in these documents
Unfortunately, paclitaxel has extreme low solubility in water, which makes it difficult to provide a suitable dosage form.
A · US 9,233,094 B2 · ¶ 5
The obvious problem, therefore, is to find methods and means to kill drug-resistant tumors, especially drug resistant cells, which are already resistant against the respective drug.
A · US 9,233,094 B2 · ¶ 7
Unfortunately, paclitaxel has extreme low solubility in water, which makes it difficult to provide a suitable dosage form.
B · US 9,827,196 B2 · ¶ 5
The obvious problem, therefore, is to find methods and means to kill drug-resistant tumors, especially drug resistant cells, which are already resistant against the respective drug.
B · US 9,827,196 B2 · ¶ 7
Cite aspatent.fyi, US 2026/0355113 A1, claim 1, first published 2026-11-19T08:28:42-05:00, https://patent.fyi/US20260355113/, SHA-256 35e7fae690496102fb88349a270cb08ccd906fe5d7ba3b0d7e4d960173eb68e0
First published
Permanent addresshttps://patent.fyi/US20260355113/
Content fingerprint (SHA-256)35e7fae690496102fb88349a270cb08ccd906fe5d7ba3b0d7e4d960173eb68e0
Methodv2026-11-18.2 · automated, not reviewed by a person
Correctionscorrections@patent.fyi